Where Discovery Becomes Diagnostic.
At the Molecular Imaging Research Centre we work with some of the UK’s highest profile institutions and companies to further the research into diseases that impact the population. Our team and facilities are available for collaborations, partnerships, and the production of radiopharmaceuticals. Discover more about our activities and the opportunities to work with us below.
A clear, confident roadmap for clinical isotope production.
Our development pipeline continues to progress on schedule, supported by strong regulatory momentum, robust market demand, and the UK’s new accelerated approval pathways. Each isotope represents a strategic milestone in expanding clinical capability and strengthening the UK’s diagnostic and theranostic infrastructure.
Clinical production forecast: May–July 2026
Gallium 68 remains firmly on track, with all technical and regulatory milestones progressing as planned. This isotope will form a cornerstone of our early clinical offering, supporting a wide range of PET imaging applications and enabling rapid deployment for partner trials
Clinical production forecast: Post August 2026
With demand for F 18 continuing to rise across the UK and Europe, our production timeline remains stable. Ongoing efficiencies in supply chain integration and licensing processes may allow for an earlier ramp up, positioning the facility as a competitive supplier in a high growth market.
Clinical production forecast: Late 2026–2027
The Iodine-124 programme, in collaboration with King’s College London and others, is a Cancer Research UK funded trial which remains on a realistic trajectory for delivery late 2026 into 2027.
Clinical production forecast: Early 2027
Carbon 11 development continues to align with early 2027 expectations, enhancing our capability in neuroscience and metabolic imaging. The first carbon-11 tracer into production will be [11C]methionine.
Expected approval: End of 2026
Our facility is progressing toward MHRA licensing with strong confidence. The regulator’s new streamlined pathways and the clearing of historic backlogs introduce a credible possibility of earlier approval, accelerating our transition into full clinical operation.
Registered office: MIRC, Daisy Building, Castle Hill Hospital, Castle Road, Cottingham HU16 5JQ.
Registered company number 177823472
Call: 01482 461909